Loading
Histone Deacetylase Inhibitors Research · Journal article
Acs Omega · August 13, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical chemistry and cell biology report identifying a novel bis-thiourea compound (compound 8) that inhibits DNA topoisomerase IIα in vitro and reduces proliferation and migration of A549 lung cancer cells through mechanisms involving cell-cycle arrest and EMT suppression. The work is exploratory and raises mechanistic hypotheses rather than establishing efficacy; it represents early lead discovery with no animal studies, clinical trials, or head-to-head comparisons to standard agents reported.
In silico molecular modeling and in vitro mechanistic study. A549 lung cancer cells and unspecified additional cancer cell lines used for cytotoxicity and mechanistic assays. Intervention: Compound 8 (bis-thiourea derivative); Topo IIα inhibitor candidate.
Compound 8 demonstrated favorable binding affinity and stability in the Topo IIα ATPase domain on molecular modeling Compound 8 inhibited Topo IIα activity in biochemical assays and showed potent cytotoxicity against cancer cell lines, particularly A549 cells Compound 8 upregulated E-cadherin and downregulated N-cadherin, vimentin, and the EMT transcription factor Slug in A549 cells
No in vivo efficacy, pharmacokinetics, or toxicology data provided; species translation is unknown. Compound 8 inhibited Topo IIα activity in biochemical assays and showed potent cytotoxicity against cancer cell lines, particularly A549 cells
This discovery-stage work does not yet support clinical decision-making. It identifies a chemical lead that warrants further preclinical validation and toxicology studies before consideration for drug development; clinicians should not anticipate near-term therapeutic availability.
Early-stage in vitro and in silico discovery study of a novel compound with no human trials, clinical outcomes, or comparative efficacy data reported.
As stated by the source record.
This discovery-stage work does not yet support clinical decision-making. It identifies a chemical lead that warrants further preclinical validation and toxicology studies before consideration for drug development; clinicians should not anticipate near-term therapeutic availability.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract DNA topoisomerase IIα (Topo IIα) is essential for maintaining genomic stability during DNA replication and mitosis and is highly expressed in cancer cells, making it a promising target for anticancer therapy. In this study, bis-thiourea derivatives were investigated for their Topo IIα inhibitory activity and anticancer potential using in silico and in vitro studies. Molecular modeling demonstrated that compound 8 exhibited favorable binding affinity and stability within the ATPase domain of Topo IIα. Biochemical assays revealed that compound 8 inhibited Topo IIα activity and showed potent cytotoxicity against several cancer cell lines, particularly A549 cells. Mechanistic studies showed that compound 8 inhibited A549 cell migration and invasion by upregulating E-cadherin while downregulating the mesenchymal markers N-cadherin and vimentin, as well as the EMT-associated transcription factor Slug. Furthermore, compound 8 induced G1-phase arrest by downregulating cyclins D1 and E2 while upregulating p21. These results suggest that compound 8 represents a promising lead for Topo IIα-targeted cancer therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.